AEON Biopharma Inc. announced recent milestones in the development of ABP-450, a biosimilar candidate to BOTOX®, aimed at achieving full-label U.S. market entry across all therapeutic indications. The company reported positive biosimilarity data in November 2025, supporting its scientific approach and readiness for regulatory engagement. AEON secured $6 million in PIPE financing with the potential for over $7 million in additional capital through warrant exercises, and reached an agreement with Daewoong for note conversion that could provide more than $8 million in potential warrant proceeds. The company's product is already authorized in 69 countries, including FDA approval in the U.S. for aesthetics under the brand Jeuveau®. AEON's next steps include an FDA Type 2a meeting scheduled for January 2026 to align on the analytical pathway for ABP-450 biosimilar development. You can access the full presentation through the link below.